SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 26.33-8.6%Jan 16 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: aknahow who wrote (10346)6/4/1999 11:52:00 AM
From: opalapril  Read Replies (3) of 17367
 
George, The endless speculation about the Phase 3 data is entertaining but in the end probably pointless.

The sad truth is statistical data can be tweaked in a variety of ways to nudge the results this way and that. From what little we do know, it seems the trial was not exactly run at all times with rigid observance of the protocol. Some who died were given Neuprex even though they weren't in the trial? Some who were logged in died right away and are being excluded from the test population?

Excluding some, including others, casting aside the protocol for humanitarian reasons, ignoring it for subjective reasons -- it all sounds like a foregone conclusion was driving someone here.

Sitting here in the statistical darkness, as we all are, I prefer to concentrate my mind on a simpler truth: the FDA asked Xoma to undertake Neuprex trials for children with meningo and gave the company every encouragement. It was a perilous undertaking for Xoma and the FDA knew it. The FDA has every incentive to be gentle with us as they review the data. Surely they know this is live or die for the company.

My money remains heavily on approval of Neuprex -- somehow, some way, for some indication, however modest.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News